There is provided polymeric nanoparticles with non-tumour antigen payloads for use in tagging cells for destruction by a subject's immune system and the use thereof for the treatment of cancer. Suitably there is provided a method of treatment comprising administration of nanoparticle comprising a non-tumour protein payload to a subject with cancer, in particular to a cancer cell.

The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.

The present invention relates to polymeric nanoparticles comprising a cytokine or a nucleic acid encoding for a cytokine, pharmaceutical compositions comprising the same, and methods for treating certain diseases comprising administering these polymeric nanoparticles to a subject in need thereof.

The present disclosure relates to compositions and methods for inhibiting L-plastin activity for inhibiting bone resorption activity of osteoclasts. In certain instances, the compositions and methods are used to treat or prevent a disease or disorder associated with bone resorption. In one aspect, the compositions and methods relate to peptide inhibitors comprising an N-terminal fragment of L-plastin.

The present application relates to nanoparticles for the targeted delivery of CRISPR/Cas13 systems, and their therapeutic use to treat diseases and disorders such as prostate cancer and COVID-19.

Compositions containing populations of nanoparticles that show selective uptake by tissues and other cell types such as lung cells and/or bone marrow cells are described. The nanoparticles show this uptake by virtue of their size and in the absence of a targeting agent on the surface of the nanoparticles, i.e., passive targeting. The population of nanoparticles contain poly(lactic acid-co-glycolic acid), have a diameter between about 70 nm and about 220 nm, and at least 90% of the nanoparticles have a diameter between about 110 nm and about 129 nm. The nanoparticles are manufactured using a microfluidic system. The compositions can be used to treat lung- and/or blood-related genetic disorders in in vivo gene editing technologies.

A precipitation route to form nanoparticles with a hydrophilic core containing water soluble materials and a hydrophobic shell is described. The process requires a stabilizing polymer composed of more polar and more non-polar regions. These regions can be arranged as a linear block copolymer, or as a comb polymer with a linear or branched polar backbone and non-polar side chains or substituents. Nucleic acids, including DNA and RNA, as well as proteins, peptides, and polysaccharides or combinations can be encapsulated in the nanoparticle core. The encapsulation of nucleic acids can require partially or fully neutralizing the acid with a base to enhance the solubility of the nucleic acid in the process solvent stream. The core or the shell of the resulting nanoparticles can be crosslinked. The nanoparticles may be coated with additional polymer to bring them into water, or processed into microparticles or larger monoliths.

A composite implant for sustained release of a therapeutic agent in an ocular area of a subject. The composite implant comprises a matrix of photopolymerized polymer formed from a photopolymerizable composition, a biodegradable polymer contained within the matrix, and a therapeutic agent dispersed or dissolved between the matrix and/or biodegradable polymer, wherein the implant is formed from an ocular composition comprising 99 to 60% (w/w) of the photopolymerizable composition. The composite implant can be used in methods of delivering a therapeutic agent to an ocular area in a subject in need thereof, particularly by injecting the implant into the ocular area. Methods of preparing the composite implant are also disclosed.

The disclosure provides self-emulsifying compositions, comprising: (i) an active pharmaceutical ingredient (API) in an amount of 1-15% by weight of the composition; (ii) one or more non-polar solvents in an amount of 20-80% by weight of the composition; and (iii) one or more surfactants in an amount of 15-70% by weight of the composition, wherein the active pharmaceutical ingredient (API) comprises cannabidiol (CBD) and wherein the one or more non-polar solvents comprise a glyceride, together with methods of making and using the same.

Compositions and methods for treating cancer that include administering a therapeutically effective amount of a tumor suppressor mRNA complexed with a delivery vehicle as described herein, e.g., a nanoparticle.